Sei Investments Co. Trims Stock Position in argenex SE $ARGX

Sei Investments Co. lessened its holdings in argenex SE (NASDAQ:ARGX) by 13.2% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 286,966 shares of the company’s stock after selling 43,540 shares during the period. Sei Investments Co.’s holdings in argenex were worth $209,556,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. M&T Bank Corp increased its holdings in argenex by 20,977.7% during the fourth quarter. M&T Bank Corp now owns 778,610 shares of the company’s stock valued at $654,772,000 after buying an additional 774,916 shares during the last quarter. Sands Capital Management LLC boosted its stake in shares of argenex by 2,046.6% during the 4th quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock worth $300,110,000 after acquiring an additional 340,245 shares during the last quarter. Invesco Ltd. grew its position in shares of argenex by 390.4% during the 4th quarter. Invesco Ltd. now owns 416,408 shares of the company’s stock valued at $350,178,000 after acquiring an additional 331,489 shares during the period. Wellington Management Group LLP grew its position in shares of argenex by 80.1% during the 3rd quarter. Wellington Management Group LLP now owns 729,986 shares of the company’s stock valued at $538,408,000 after acquiring an additional 324,653 shares during the period. Finally, Two Sigma Investments LP grew its position in shares of argenex by 570.3% during the 3rd quarter. Two Sigma Investments LP now owns 294,160 shares of the company’s stock valued at $216,961,000 after acquiring an additional 250,278 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

argenex Price Performance

Shares of NASDAQ ARGX opened at $851.72 on Thursday. The firm has a fifty day moving average price of $863.85 and a 200-day moving average price of $813.80. The stock has a market cap of $53.28 billion, a PE ratio of 37.92, a price-to-earnings-growth ratio of 1.08 and a beta of 0.45. argenex SE has a 1 year low of $566.42 and a 1 year high of $953.58.

argenex (NASDAQ:ARGX) last announced its quarterly earnings data on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion for the quarter. On average, research analysts expect that argenex SE will post 26.33 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently commented on ARGX shares. Royal Bank Of Canada raised their target price on argenex from $890.00 to $945.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Wedbush reissued an “outperform” rating and set a $1,000.00 price target on shares of argenex in a report on Thursday, June 11th. Morgan Stanley upped their price target on argenex from $1,170.00 to $1,180.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. HC Wainwright reaffirmed a “buy” rating and issued a $940.00 price objective on shares of argenex in a research note on Thursday, June 25th. Finally, Oppenheimer decreased their price objective on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a research note on Thursday, April 2nd. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,042.67.

About argenex

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.